What viral markers are linked to a higher risk of getting nasopharyngeal carcinoma?
Nasopharyngeal carcinoma (NPC) is strongly linked to Epstein-Barr virus (EBV) infection. Certain viral markers, such as antibodies to EBV proteins and EBV DNA in the blood, can indicate a higher risk of developing NPC. These markers are used in research and screening to identify people who may be at increased risk.
What the research says
A mini review of genetic and viral factors found that markers linked to EBV, including LMP1, EBNA1, and circulating plasma EBV DNA, show a consistent association with NPC susceptibility 5. A nested case-control study tested a strip assay for antibodies to EBNA1, an EBV protein. It found that IgA antibodies to a specific part of EBNA1 (dGAr) had 85% sensitivity and about 94% specificity for detecting NPC within 4 years before diagnosis. People positive for both EBNA1 FL and dGAr had a 243 times higher odds of NPC compared to those negative for both 3. Another review on epigenetic changes in NPC also notes that EBV infection is a key factor, and that viral markers are being developed for early detection 1. These findings support using EBV antibodies and DNA as risk markers.
What to ask your doctor
- Should I be tested for EBV antibodies, such as IgA against EBNA1, to assess my NPC risk?
- What does a positive EBV antibody test mean for my personal risk of NPC?
- Is there a role for circulating EBV DNA testing in my situation?
- How often should I be screened if I have risk factors like EBV infection or family history?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.